Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is identified as one of the 7 Oversold Pharma Stocks to Buy Now, with Truist lowering its price target on NBIX to $140 from $169 following a 2026 outlook update. The company’s fourth-quarter results led to strong top-line growth, with overall net product sales increasing by 29% and 22% year over year to $798.3 million in Q4 and $2.83 billion for the entire year. INGREZZA generated $657.5 million in fourth-quarter sales and $2.51 billion for the full year, while CRENESSITY contributed $135.3 million in Q4 sales and $301.2 million for the year. Neurocrine Biosciences is a biopharmaceutical company focusing on innovative therapies for neurological and endocrine-related disorders.

Read more at Yahoo Finance: Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update